Novan (NOVN) Reports First Patient Enrolled & Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
- S&P 500, Nasdaq close at fresh records on AI boost, easing yields
- Goldman removes Apple stock from 'US Conviction List - Directors' Cut'
- Boeing in talks to acquire Spirit AeroSystems, analysts discuss 'negative' financial benefits
- Stocks climb, yields fall as data supports rate cut bets
- Dell tops estimates on boost from AI-led server demand, shares jump premarket
Novan, Inc. (NASDAQ: NOVN), today announced the first patient has been enrolled and dosed in its B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”).
Molluscum contagiosum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years.
“I believe that the design of the B-SIMPLE4 study positions us well to fully evaluate SB206 for the treatment of molluscum,” commented Elizabeth Messersmith, Ph.D, Senior Vice President and Chief Development Officer of Novan. “We are encouraged by the trends in efficacy as well as the safety profile SB206 has demonstrated to-date and look forward to continuing to advance development of this important program where there remains no FDA approved treatment.”
Completion of patient enrollment is targeted for the first quarter of 2021. Topline results from the B-SIMPLE4 trial are anticipated in the second quarter of 2021, subject to the targeted timing and trial execution plan which have been and may be further impacted by the COVID-19 pandemic.
There are currently no FDA-approved therapies for the treatment of molluscum. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would satisfy an important patient-care need for the treatment of molluscum.
For more information about the trial, please visit clinicaltrials.gov and reference identifier: NCT04535531.
Molluscum contagiosum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years. Infected children typically present with 10 to 30 painless, yet unsightly lesions, and, in severe cases, they can have around 100 lesions. Due to the largely pediatric nature of the disease, parents are the caregivers for these children, in most cases, and tend to seek treatment. There are no FDA-approved therapies for molluscum, and, upon seeking treatment, caregivers are faced with potentially painful in-office, dermatologist-administered physical procedures or cantharidin, or recommended off-label prescriptions and over-the-counter products. More than half of the patients diagnosed with molluscum are untreated and over 30% of those treated receive an off-label prescription with no molluscum indication or proven clinical efficacy. The average time to resolution is 13 months, however, some children experience lesions that may not resolve in 24 months. Further dissemination of this highly-contagious disease is common, and transmission to other children living in the household is reported to be 41%. There is a significant unmet need in the molluscum treatment landscape.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aadi Bioscience (AADI) Announces Publication of Long-Term Efficacy and Safety Data Supporting FYARRO
- Ironwood Pharma (IRWD) Reports Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide
- Johnson & Johnson (JNJ) Announces FDA Approval of RYBREVANT + chemotherapy
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!